华南预防医学 ›› 2025, Vol. 51 ›› Issue (10): 1098-1102.doi: 10.12183/j.scjpm.2025.1098

• 论著 • 上一篇    下一篇

基于颈动脉高分辨率MRI的易损斑块筛查对TIA/轻型卒中患者健康管理预防效果评估

袁红梅, 强孔俊, 陈丽薇   

  1. 黄河三门峡医院,河南 三门峡 472000
  • 收稿日期:2025-03-13 出版日期:2025-10-20 发布日期:2025-11-14
  • 作者简介:袁红梅(1982—),女,硕士研究生,主治医师,研究方向为胸腹部疾病及血管疾病影像诊断
  • 基金资助:
    2024年度河南省医学科技攻关计划项目(LHGJ20240687)

Evaluation of the efficacy of health management and prevention strategies in patients with TIA/minor stroke based on vulnerable plaque screening via carotid high-resolution MRI

YUAN Hongmei, QIANG Kongjun, CHEN Liwei   

  1. Yellow River Sanmenxia Hospital, Sanmenxia, Henan 472000, China
  • Received:2025-03-13 Online:2025-10-20 Published:2025-11-14

摘要: 目的 探讨基于颈动脉高分辨率磁共振成像(HRCMRI)的易损斑块筛查对短暂性脑缺血发作(TIA)/轻型卒中患者二级预防效果影响。方法 选取2021年2月-2024年2月医院收治的TIA/轻型卒中患者作为研究对象,根据患者意愿分为414例对照组、420例观察组,倾向性评分匹配法对2组患者基线资料进行1∶; 1匹配,2组各392例配对后入组。对照组根据现行指南进行标准预防性治疗和随访,观察组基于HRCMRI的易损斑块筛查分为高风险组、低风险组,并予以针对性预防性策略。对比2组的卒中复发率、用药依从性、影像学特征、不良反应、成本效益。结果 对照组、观察组分别有32例、14例失访。观察组出院后1年的复发率低于对照组,复发时间间隔长于对照组(P<; 0.05)。治疗后,2组斑块厚度、斑块长度、斑块内出血、纤维帽断裂均较治疗前降低(P<; 0.05)。观察组的用药依从率高于对照组(P<; 0.05)。2组的各种不良反应发生率差异无统计学意义(P>; 0.05)。成本-效果分析:ΔC/ΔE为219.80元/%,即多花费219.80元,可多预防1例卒中复发,提示观察组的治疗策略具有更明显的成本-效果优势。结论 基于HRCMRI的易损斑块筛查应用于TIA/轻型卒中患者二级预防中,可降低其卒中复发率,改善斑块稳定性,提高用药依从性,不增加不良反应,且具有更明显的成本-效果优势。

关键词: 短暂性脑缺血发作, 轻型卒中, 颈动脉高分辨率MRI, 易损斑块, 二级预防效果

Abstract: Objective To investigate the impact of vulnerable plaque screening using carotid high-resolution magnetic resonance imaging (HR-CMR) on the effectiveness of secondary prevention in patients with transient ischemic attack (TIA)/minor stroke. Methods Patients with TIA/minor stroke admitted to our hospital between February 2021 and February 2024 was enrolled. Based on patient preference, they were allocated to a control group (n=414) or an observation group (n=420). A 1∶1 propensity score matching was performed to balance the baseline characteristics, resulting in 392 matched pairs in each group. The control group received standard secondary prevention therapy and follow-up according to established clinical guidelines. In the observation group, patients were stratified into high-risk and low-risk subgroups based on the findings of vulnerable plaque screening via HR-CMR and received targeted preventive strategies accordingly. The outcomes of interest, including stroke recurrence rates, medication adherence, imaging characteristics, adverse events, and cost-effectiveness, were compared between the two groups. Results In the final analysis, 32 patients from the control group and 14 from the observation group were lost to follow-up. The one-year stroke recurrence rate in the observation group was significantly lower than that in the control group, and the time to recurrence was longer (P<0.05). Post-intervention, both groups exhibited a reduction in plaque thickness, plaque length, intraplaque hemorrhage, and fibrous cap rupture compared to baseline; however, these improvements were significantly more pronounced in the observation group (P<0.05). Medication adherence was significantly higher in the observation group compared to the control group (P<0.05). There was no statistically significant difference in the incidence of various adverse reactions between the two groups (P>0.05). A cost-effectiveness analysis revealed an incremental cost-effectiveness ratio (ICER) of 219.80 RMB/% (ΔC/ΔE), indicating that an additional expenditure of 219.80 RMB was associated with the prevention of one additional case of stroke recurrence. This suggests a superior cost-effectiveness advantage for the intervention strategy employed in the observation group. Conclusions The application of vulnerable plaque screening based on HR-CMR in the secondary prevention of TIA/minor stroke can effectively reduce the rate of stroke recurrence, enhance plaque stability, and improve medication adherence without increasing the incidence of adverse events. Furthermore, this approach demonstrates a notable cost-effectiveness advantage.

Key words: Transient ischemic attack, Minor stroke, Carotid high-resolution MRI, Vulnerable plaque, Secondary prevention efficacy

中图分类号: 

  • R743.3